Prestige Biologics Co., Ltd. (KOSDAQ:334970)
South Korea · Delayed Price · Currency is KRW 1,408.00
+2.00 (0.14%)
At close: Oct 8, 2026
Prestige Biologics Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 |
Operating Revenue | 26,665 | 12,533 | 2,169 | 1,746 | 15.57 |
Other Revenue | - | - | - | -0 | -0 |
| 26,665 | 12,533 | 2,169 | 1,746 | 15.57 | |
Revenue Growth | 112.76% | 477.82% | 24.24% | 11115.88% | -99.52% |
Cost of Revenue | 46,082 | 28,517 | 11,013 | 1,252 | 24.28 |
Gross Profit | -19,417 | -15,984 | -8,844 | 493.75 | -8.71 |
Selling, General & Admin | 5,649 | 8,992 | 9,695 | 7,639 | 5,202 |
Research & Development | 20,220 | 2,588 | 9,301 | 31,848 | 30,970 |
Amortization of Goodwill & Intangibles | 50.24 | 49.06 | 51.91 | 47.89 | 49.36 |
Other Operating Expenses | 267.15 | 340.46 | 417.59 | 237.71 | 180.45 |
Operating Expenses | 29,885 | 17,698 | 24,586 | 40,536 | 36,623 |
Operating Income | -49,302 | -33,682 | -33,430 | -40,043 | -36,631 |
Interest Expense | -6,917 | -8,734 | -11,769 | -5,273 | -3,929 |
Interest & Investment Income | 47.49 | 519.37 | 1,468 | 853.79 | 700.85 |
Currency Exchange Gain (Loss) | -267.18 | 3,243 | -4,690 | -4,624 | -9,537 |
Other Non Operating Income (Expenses) | 10,456 | 11,191 | 18,957 | 10,222 | 257.62 |
EBT Excluding Unusual Items | -45,982 | -27,463 | -29,465 | -38,863 | -49,138 |
Gain (Loss) on Sale of Assets | -1.74 | -6.86 | 90.87 | 67.29 | 66.42 |
Asset Writedown | -5,236 | - | - | -646.03 | -646.03 |
Pretax Income | -51,220 | -27,469 | -29,374 | -39,442 | -49,718 |
Net Income | -51,220 | -27,469 | -29,374 | -39,442 | -49,718 |
Net Income to Common | -51,220 | -27,469 | -29,374 | -39,442 | -49,718 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 78 | 74 | 61 | 59 | 52 |
Shares Outstanding (Diluted) | 78 | 74 | 61 | 59 | 52 |
Shares Change | 5.54% | 20.22% | 4.43% | 13.35% | 16.43% |
EPS (Basic) | -659.00 | -373.00 | -479.50 | -672.37 | -960.73 |
EPS (Diluted) | -659.00 | -373.00 | -479.50 | -672.37 | -960.73 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | 910.95 | -23,534 | -16,867 | -60,265 | -118,767 |
Free Cash Flow Per Share | 11.72 | -319.56 | -275.34 | -1027.35 | -2295.00 |
Gross Margin | -72.82% | -127.53% | - | 28.28% | -55.97% |
Operating Margin | -184.89% | -268.74% | -1541.23% | -2293.61% | -235333.31% |
Profit Margin | -192.09% | -219.17% | -1354.23% | -2259.19% | -319407.01% |
Free Cash Flow Margin | 3.42% | -187.77% | -777.63% | -3451.94% | -763002.69% |
EBITDA | -32,437 | -20,598 | -22,199 | -31,629 | -28,693 |
EBITDA Margin | -121.64% | -164.35% | - | - | - |
D&A For EBITDA | 16,865 | 13,083 | 11,231 | 8,414 | 7,938 |
EBIT | -49,302 | -33,682 | -33,430 | -40,043 | -36,631 |
EBIT Margin | -184.89% | -268.74% | - | - | - |
Advertising Expenses | 97.35 | 101.46 | 308.97 | - | 53.15 |